Commentary: will it take Harry Potter to solve diabetes? Divining the future of diabetes care.
Moses
Alan C
AC
Novo Nordisk, North America, Princeton, NJ 08540, USA. ALNM@novonordisk.com
D001786:Blood Glucose / Q000187:drug effects; D048909:Diabetes Complications / Q000517:prevention & control; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D005544:Forecasting; D052216:Glucagon-Like Peptide 1 / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D050417:Insulin-Secreting Cells / Q000378:metabolism
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D052216:Glucagon-Like Peptide 1